Abstract
In this paper, an extended review analysis has been presented concerning the developments in brain drug delivery through new and efficient applications of nanotechnology. Modern nanotechnological approaches for the diagnosis and treatment of Alzheimer's and Parkinson's diseases are described along with simultaneous analysis of safety and practical clinical usage of these strategies.
Keywords: Nanotechnology, nanomedicine, neurodegenerative diseases, Alzheimer’s disease, Parkinson’s disease.
Current Drug Metabolism
Title:Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease
Volume: 16 Issue: 8
Author(s): Georgia Soursou, Athanasios Alexiou, Ghulam Md Ashraf, Asad Ali Siyal, Gohar Mushtaq and Mohammad A. Kamal
Affiliation:
Keywords: Nanotechnology, nanomedicine, neurodegenerative diseases, Alzheimer’s disease, Parkinson’s disease.
Abstract: In this paper, an extended review analysis has been presented concerning the developments in brain drug delivery through new and efficient applications of nanotechnology. Modern nanotechnological approaches for the diagnosis and treatment of Alzheimer's and Parkinson's diseases are described along with simultaneous analysis of safety and practical clinical usage of these strategies.
Export Options
About this article
Cite this article as:
Soursou Georgia, Alexiou Athanasios, Ashraf Md Ghulam, Siyal Ali Asad, Mushtaq Gohar and Kamal A. Mohammad, Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease, Current Drug Metabolism 2015; 16 (8) . https://dx.doi.org/10.2174/138920021608151107125049
DOI https://dx.doi.org/10.2174/138920021608151107125049 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Impact of brain tissue binding and plasma protein binding of drugs in DMPK
The impression of brain tissue binding (BTB) or plasma protein binding (PPB) in Drug Metabolism and Pharmacokinetics is critical to understanding the distribution, efficacy, and potential toxicity of drugs that target the central nervous system (CNS). BTB and high PPB influence the distribution of drugs in the body and their ...read more
Interaction Between Drugs and Endocrine Diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Metabolism-Mediated Xenobiotic Toxicity
Considering the potent modulation of biotransformation enzyme expression and activities by various therapeutic drugs and environmental chemicals, and the commonly combined exposure of humans to both drugs and the ever increasing environmental pollutants simultaneously, knowledge about the combined toxic effects by modulating biotransformation enzymes, such as P450s, UDP- glucuronosyltransferases, and ...read more
Safety evaluation of vaccine combination
Vaccine combination safety evaluation is a critical field within immunology and public health that focuses on assessing the safety and efficacy of combining different vaccines to maximize protection against various diseases while minimizing potential adverse effects. This process is significant because it ensures that vaccines can be administered together without ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index to Volume 3
Current Medicinal Chemistry - Central Nervous System Agents Synthesis of L-Dopa Modifier L-Dopa-L-His and its Interaction with DNA
Letters in Organic Chemistry New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects
Current Medicinal Chemistry The Role of Neurogenesis in Neurodegenerative Diseases and its Implications for Therapeutic Development
CNS & Neurological Disorders - Drug Targets Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis
Current Pharmaceutical Design Takotsubo Cardiomyopathy: What we have Learned in the Last 25 Years? (A Comparative Literature Review)
Current Cardiology Reviews New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
Current Neuropharmacology Genetic Variants in Diseases of the Extrapyramidal System
Current Genomics Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions
Current Medicinal Chemistry Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders
Recent Patents on CNS Drug Discovery (Discontinued) An Overview of Pharmacological and Clinical Aspects of <i>Spirulina</i>
Current Drug Discovery Technologies Selective Targeting of Muscarinic Receptors: Novel Therapeutic Approaches for Psychotic Disorders
Current Neuropharmacology Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease
Current Drug Metabolism Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
Current Pharmaceutical Design Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs
CNS & Neurological Disorders - Drug Targets Role of Dopamine Signaling in Drug Addiction
Current Topics in Medicinal Chemistry Natural Products Combating Neurodegeneration: Parkinson’s Disease
Current Drug Metabolism Classical Neurotransmitters and Neuropeptides Involved in Parkinson's Disease: Focus on Anti-Parkinsonian Drugs
Current Drug Therapy Aripiprazole in Children and Adolescents with Schizophrenia
Current Psychopharmacology Lower K<sub>V</sub>7.5 Potassium Channel Subunit Expression in an Animal Model of Paroxysmal Dystonia
CNS & Neurological Disorders - Drug Targets